We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M Turnover 44%
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
-11.22%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$192M
AUM Growth
-$269M
Cap. Flow
-$30M
Cap. Flow %
-15.64%
Top 10 Hldgs %
57.46%
Holding
50
New
8
Increased
10
Reduced
11
Closed
17
Avg Time Held Equity + Options
1 year
Top 10 Avg Time Held Equity + Options
0.2 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
1.1 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.8 years

Sector Composition

Rank Sector Weight
1 Healthcare 75.76%
2 Miscellaneous 24.24%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.9B
$29.7M 15.47%
+400,000
New +$30M
2022 Q2
0 quarters
CLDX icon
2
CALL
Celldex Therapeutics
CLDX
$2.2B
$10.8M 5.62%
+400,000
New +$11.6M
2022 Q2
0 quarters
FOLD icon
3
DELISTED
Amicus Therapeutics
FOLD
$10.7M 5.59%
1,000,000
-100,000
-9% -$824K
2020 Q3
7 quarters
APLS icon
4
DELISTED
Apellis Pharmaceuticals
APLS
$10.2M 5.3%
225,000
-25,000
-10% -$1.14M
2021 Q3
3 quarters
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.56B
$9.7M 5.08%
130,000
+80,000
+160% +$5.89M
2021 Q4
2 quarters
AXSM icon
6
Axsome Therapeutics
AXSM
$7.06B
$8.62M 4.49%
225,000
+130,500
+138% +$4.13M
2022 Q1
1 quarter
COGT icon
7
Cogent Biosciences
COGT
$4.87B
$8.12M 4.23%
900,000
-800,000
-47% -$5.46M
2020 Q4
6 quarters
HZNP
8
DELISTED
Horizon Therapeutics
HZNP
$7.98M 4.15%
+100,000
New +$9.47M
2022 Q2
0 quarters
MRTX
9
DELISTED
Mirati Therapeutics
MRTX
$7.38M 3.85%
110,000
+90,000
+450% +$5.72M
2017 Q4
18 quarters
PCVX icon
10
Vaxcyte
PCVX
$9.41B
$7.07M 3.68%
325,000
+25,000
+8% +$579K
2021 Q2
4 quarters
ASND icon
11
Ascendis Pharma
ASND
$17.4B
$6.97M 3.63%
75,000
-65,000
-46% -$6.13M
2017 Q3
19 quarters
VRDN icon
12
Viridian Therapeutics
VRDN
$3.5B
$6.94M 3.62%
600,000
+133,597
+29% +$1.8M
2021 Q1
5 quarters
SGEN
13
DELISTED
Seagen
SGEN
$6.19M 3.23%
+35,000
New +$5.04M
2022 Q2
0 quarters
KRTX icon
14
DELISTED
Karuna Therapeutics
KRTX
$5.69M 2.97%
45,000
-15,000
-25% -$1.72M
2022 Q1
1 quarter
MRUS icon
15
DELISTED
Merus
MRUS
$5.66M 2.95%
250,000
-150,000
-38% -$3.13M
2021 Q2
4 quarters
ISEE
16
DELISTED
IVERIC bio
ISEE
$4.81M 2.51%
500,000
+50,000
+11% +$628K
2019 Q4
10 quarters
CTIC
17
DELISTED
CTI BioPharma
CTIC
$4.78M 2.49%
800,000
-500,000
-38% -$2.56M
2020 Q4
6 quarters
RLMD icon
18
Relmada Therapeutics
RLMD
$318M
$4.75M 2.47%
250,000
+150,000
+150% +$3.27M
2021 Q3
3 quarters
ARVN icon
19
Arvinas
ARVN
$439M
$4.63M 2.41%
110,000
– –
2018 Q3
15 quarters
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$799M
$4.33M 2.25%
225,000
– –
2020 Q1
9 quarters
DSGN icon
21
Design Therapeutics
DSGN
$608M
$3.85M 2.01%
275,000
+75,000
+38% +$1.01M
2021 Q4
2 quarters
KZR icon
22
DELISTED
Kezar Life Sciences
KZR
$3.72M 1.94%
45,000
+5,000
+13% +$441K
2021 Q4
2 quarters
XBI icon
23
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.9B
$3.71M 1.93%
50,000
-250,000
-83% -$18.8M
2022 Q1
1 quarter
BCRX icon
24
BioCryst Pharmaceuticals
BCRX
$1.9B
$3.44M 1.79%
325,000
-25,000
-7% -$258K
2022 Q1
1 quarter
RAPT icon
25
DELISTED
RAPT Therapeutics
RAPT
$3.01M 1.57%
20,625
-10,625
-34% -$1.42M
2021 Q2
4 quarters

Similar funds

Ghost Tree Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Ghost Tree Capital held 50 positions worth $192M, down 58% from $461M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Ghost Tree Capital withdrew a net $30M in Q2 2022, closing 17 positions and reducing 11 holdings. Its most notable exit was Sierra Oncology, an estimated $10.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 43% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Ghost Tree Capital opened a new position in Horizon Therapeutics worth $7.98M.

  • Ghost Tree Capital's largest Q2 2022 buy was Horizon Therapeutics: 100,000 shares worth $7.98M.
  • Ghost Tree Capital added most to Sarepta Therapeutics in Q2 2022, an estimated $5.89M increase.
  • Ghost Tree Capital's biggest Q2 2022 reduction was Ascendis Pharma, cutting an estimated $6.13M.
  • Ghost Tree Capital fully exited Sierra Oncology in Q2 2022, selling an estimated $10.4M.
  • Ghost Tree Capital's ten largest holdings make up 57% of its $192M portfolio in Q2 2022.
  • Ghost Tree Capital opened 8 new positions and closed 17 in Q2 2022.
  • Ghost Tree Capital's portfolio value fell 58% quarter-over-quarter to $192M.

Based on Ghost Tree Capital's 13F filing for Q2 2022, filed 15 Aug 2022.